Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Plasma-Lyte R
Overview
What is Plasma-Lyte R?
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) is a sterile,
nonpyrogenic isotonic solution in a single dose container for
intravenous administration. Each 100 mL contains 640 mg of Sodium
Acetate Trihydrate, USP
(CHNaO•3HO); 496 mg
of Sodium Chloride, USP (NaCl); 89.6 mg of Sodium Lactate
(CHNaO); 74.6 mg of Potassium
Chloride, USP (KCl); 36.8 mg of Calcium Chloride, USP
(CaCl•2HO); and 30.5 mg of Magnesium
Chloride, USP (MgCl•6HO). It contains no
antimicrobial agents. The pH is adjusted with hydrochloric acid. The pH
is 5.5 (4.0 to 8.0).
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) administered
intravenously has value as a source of water, electrolytes, and
calories. One liter has an ionic concentration of 140 mEq sodium, 10 mEq
potassium, 5 mEq calcium, 3 mEq magnesium, 103 mEq chloride, 47 mEq
acetate, and 8 mEq lactate. The osmolarity is 312 mOsmol/L (calc).
Normal physiologic osmolarity range is approximately 280 to 310
mOsmol/L. Administration of substantially hypertonic solutions may cause
vein damage. The caloric content is 11 kcal/L.
The VIAFLEX plastic
container is fabricated from a specially formulated polyvinyl chloride
(PL 146 Plastic). The amount of water that can permeate from inside the
container into the overwrap is insufficient to affect the solution
significantly. Solutions in contact with the plastic container can leach
out certain of its chemical components in very small amounts within the
expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts
per million. However, the safety of the plastic has been confirmed in
tests in animals according to USP biological tests for plastic
containers as well as by tissue culture toxicity studies.
What does Plasma-Lyte R look like?
What are the available doses of Plasma-Lyte R?
Sorry No records found.
What should I talk to my health care provider before I take Plasma-Lyte R?
Sorry No records found
How should I use Plasma-Lyte R?
Sorry No records found
What interacts with Plasma-Lyte R?
None known
What are the warnings of Plasma-Lyte R?
Trovafloxacin has not been shown to be effective in the treatment of syphilis. Antimicrobial agents used in high doses for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis.
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) should be used
with great care, if at all, in patients with congestive heart failure,
severe renal insufficiency and in clinical states in which there exists
edema with sodium retention.
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) should be used
with great care, if at all, in patients with hyperkalemia, severe renal
failure and in conditions in which potassium retention is present.
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) should be used
with great care in patients with metabolic or respiratory alkalosis. The
administration of lactate or acetate ions should be done with great care
in those conditions in which there is an increased level or an impaired
utilization of these ions, such as severe hepatic insufficiency.
PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP)
should not be administered simultaneously with blood through the same
administration set because of the likelihood of coagulation.
The intravenous
administration of PLASMA-LYTE R Injection (Multiple Electrolytes
Injection, Type 2, USP) can cause fluid and/or solute overloading
resulting in dilution of serum electrolyte concentrations,
overhydration, congested states or pulmonary edema. The risk of
dilutional states is inversely proportional to the electrolyte
concentrations of the injection. The risk of solute overload causing
congested states with peripheral and pulmonary edema is directly
proportional to the electrolyte concentrations of the injection.
In patients with
diminished renal function, administration of PLASMA-LYTE R Injection
(Multiple Electrolytes Injection, Type 2, USP) may result in sodium or potassium retention. PLASMA-LYTE R Injection (Multiple Electrolytes
Injection, Type 2, USP) is not for use in the treatment of lactic
acidosis.
What are the precautions of Plasma-Lyte R?
Clinical evaluation
and periodic laboratory determinations are necessary to monitor changes
in fluid balance, electrolyte concentrations and acid base balance
during prolonged parenteral therapy or whenever the condition of the
patient warrants such evaluation.
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) should be used
with caution. Excess administration may result in metabolic alkalosis.
Caution must be
exercised in the administration of PLASMA-LYTE R Injection (Multiple
Electrolytes Injection, Type 2, USP) to patients receiving
corticosteroids or corticotropin.
Pregnancy
Pediatric Use
Safety and
effectiveness of PLASMA-LYTE R Injection (Multiple Electrolytes
Injection, Type 2, USP) in pediatric patients have not been
established by adequate and well controlled trials, however, the
use of electrolyte solutions in the pediatric population is
referenced in the medical literature. The warnings, precautions
and adverse reactions identified in the label copy should be
observed in the pediatric population.
Geriatric Use
Clinical
studies of PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) did not include sufficient numbers of
subjects aged 65 and over to determine whether they respond
differently from younger subjects. Other reported clinical
experience has not identified differences in responses between
the elderly and younger patients. In general, dose selection for
an elderly patient should be cautious, usually starting at the
low end of the dosing range, reflecting the greater frequency of
decreased hepatic, renal, or cardiac function, and of
concomitant disease or drug therapy.
Do not administer unless solution is clear and seal is
intact.
What are the side effects of Plasma-Lyte R?
Reactions which may
occur because of the solution or the technique of administration include
febrile response, infection at the site of injection, venous thrombosis
or phlebitis extending from the site of injection, extravasation and
hypervolemia.
If an adverse
reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures and save the remainder
of the fluid for examination if deemed necessary.
What should I look out for while using Plasma-Lyte R?
None
known
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) should be used
with great care, if at all, in patients with congestive heart failure,
severe renal insufficiency and in clinical states in which there exists
edema with sodium retention.
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) should be used
with great care, if at all, in patients with hyperkalemia, severe renal
failure and in conditions in which potassium retention is present.
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) should be used
with great care in patients with metabolic or respiratory alkalosis. The
administration of lactate or acetate ions should be done with great care
in those conditions in which there is an increased level or an impaired
utilization of these ions, such as severe hepatic insufficiency.
PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP)
should not be administered simultaneously with blood through the same
administration set because of the likelihood of coagulation.
The intravenous
administration of PLASMA-LYTE R Injection (Multiple Electrolytes
Injection, Type 2, USP) can cause fluid and/or solute overloading
resulting in dilution of serum electrolyte concentrations,
overhydration, congested states or pulmonary edema. The risk of
dilutional states is inversely proportional to the electrolyte
concentrations of the injection. The risk of solute overload causing
congested states with peripheral and pulmonary edema is directly
proportional to the electrolyte concentrations of the injection.
In patients with
diminished renal function, administration of PLASMA-LYTE R Injection
(Multiple Electrolytes Injection, Type 2, USP) may result in sodium or potassium retention. PLASMA-LYTE R Injection (Multiple Electrolytes
Injection, Type 2, USP) is not for use in the treatment of lactic
acidosis.
What might happen if I take too much Plasma-Lyte R?
Sorry No Records found
How should I store and handle Plasma-Lyte R?
PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) in VIAFLEX plastic containers is available as shown below:Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) in VIAFLEX plastic containers is available as shown below:Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) has value as a
source of water and electrolytes. It is capable of inducing diuresis
depending on the clinical condition of the patient.
PLASMA-LYTE R
Injection (Multiple Electrolytes Injection, Type 2, USP) produces a
metabolic alkalinizing effect. Acetate and lactate ions are metabolized
ultimately to carbon dioxide and water, which requires the consumption
of hydrogen cations.
Non-Clinical Toxicology
None knownPLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.
PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate or acetate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency. PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) should not be administered simultaneously with blood through the same administration set because of the likelihood of coagulation.
The intravenous administration of PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection.
In patients with diminished renal function, administration of PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) may result in sodium or potassium retention. PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) is not for use in the treatment of lactic acidosis.
Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra), as well as sucralfate and iron (ferrous ions). These agents as well as formulations containing divalent and trivalent cations such as Videx, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution, should be taken at least 2 hours before or 2 hours after oral trovafloxacin administration. (See .)
Morphine: Co-administration of intravenous morphine significantly reduces the absorption of oral trovafloxacin. Intravenous morphine should be administered at least 2 hours after oral TROVAN dosing in the fasted state and at least 4 hours after oral TROVAN is taken with food. Trovafloxacin administration had no effect on the pharmacokinetics of morphine or its metabolite, morphine-6-β-glucuronide. (See .)
Warfarin: There have been reports during the post-marketing experience that trovafloxacin/alatrofloxacin enhance the effects of warfarin, including cases of bleeding. The mechanism for this reaction is unknown. Prothrombin time, International Normalized Ratio (INR) or other suitable anticoagulation tests should be closely monitored if trovafloxacin/alatrofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding.
Minor pharmacokinetic interactions without clinical significance have been observed with co-administration of TROVAN Tablets with caffeine, omeprazole and calcium carbonate. (See .)
No significant pharmacokinetic interactions with theophylline, cimetidine, digoxin, warfarin, or cyclosporine have been observed with TROVAN Tablets. (See .)
Alatrofloxacin should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line. (See .)
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) should be used with caution. Excess administration may result in metabolic alkalosis.
Caution must be exercised in the administration of PLASMA-LYTE R Injection (Multiple Electrolytes Injection, Type 2, USP) to patients receiving corticosteroids or corticotropin.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).